Mammalian Target of Rapamycin Inhibitors Vs Calcineurin Inhibitors in Chronic Graft Rejection After Lung Transplantation: A Systematic Review and Meta‐Analysis

•Mammalian target of rapamycin (mTOR) inhibitors indicated a risk of death 12 months after lung transplant.•mTOR inhibitors indicated a greater trend toward the risk of acute lung rejection.•There is no significant chronic graft rejection up to 12 months of treatment.•mTOR inhibitors favor an increase in the risk of experiencing adverse events.•mTOR inhibitors recommended for patients with renal dysfunction after use of calcineurin inhibitors.